Clal Biotechnology Shares Outstanding vs. Current Valuation
| CBI Stock | 36.80 0.80 2.13% |
For Clal Biotechnology profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Clal Biotechnology to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Clal Biotechnology Industries utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Clal Biotechnology's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Clal Biotechnology Industries over time as well as its relative position and ranking within its peers.
Clal |
Clal Biotechnology Current Valuation vs. Shares Outstanding Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining Clal Biotechnology's current stock value. Our valuation model uses many indicators to compare Clal Biotechnology value to that of its competitors to determine the firm's financial worth. Clal Biotechnology Industries is number one stock in shares outstanding category among its peers. It also is the top company in current valuation category among its peers reporting about 0.57 of Current Valuation per Shares Outstanding. The ratio of Shares Outstanding to Current Valuation for Clal Biotechnology Industries is roughly 1.76 . Comparative valuation analysis is a catch-all model that can be used if you cannot value Clal Biotechnology by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Clal Biotechnology's Stock. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued.Clal Current Valuation vs. Shares Outstanding
Outstanding Shares are shares of common stock of a public company that were purchased by investors after they were authorized and issued by the company to the public. Outstanding Shares are typically reported on fully diluted basis, including exotic instruments such as options, or convertibles bonds.
Clal Biotechnology |
| = | 156.85 M |
Outstanding shares that are stated on company Balance Sheet are used when calculating many important valuation and performance indicators including Return on Equity, Market Cap, EPS and many others.
Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Clal Biotechnology |
| = | 89.12 M |
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
Clal Current Valuation vs Competition
Clal Biotechnology Industries is the top company in current valuation category among its peers. After adjusting for long-term liabilities, total market size of Health Care industry is currently estimated at about 39.88 Billion. Clal Biotechnology adds roughly 89.12 Million in current valuation claiming only tiny portion of equities under Health Care industry.
Clal Biotechnology Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in Clal Biotechnology, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Clal Biotechnology will eventually generate negative long term returns. The profitability progress is the general direction of Clal Biotechnology's change in net profit over the period of time. It can combine multiple indicators of Clal Biotechnology, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
Clal Biotechnology Industries Ltd. is a private equity and venture capital firm specializing in development stage, pre-clinical incubation, seed, start-up, early venture, emerging growth, mid venture, late venture, PIPEs, and growth capital stages of financing. It operates as a subsidiary of Clal Industries and Investments Ltd. CLAL BIOTECHNOLOGY operates under Biotechnology classification in Israel and is traded on Tel Aviv Stock Exchange.
Clal Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on Clal Biotechnology. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Clal Biotechnology position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Clal Biotechnology's important profitability drivers and their relationship over time.
Use Clal Biotechnology in pair-trading
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Clal Biotechnology position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Clal Biotechnology will appreciate offsetting losses from the drop in the long position's value.Clal Biotechnology Pair Trading
Clal Biotechnology Industries Pair Trading Analysis
The ability to find closely correlated positions to Clal Biotechnology could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Clal Biotechnology when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Clal Biotechnology - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Clal Biotechnology Industries to buy it.
The correlation of Clal Biotechnology is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Clal Biotechnology moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Clal Biotechnology moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Clal Biotechnology can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Use Investing Themes to Complement your Clal Biotechnology position
In addition to having Clal Biotechnology in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Large Cap ETFs Thematic Idea Now
Large Cap ETFs
ETF themes focus on helping investors to gain exposure to a broad range of assets, diversify, and lower overall costs. The Large Cap ETFs theme has 676 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Large Cap ETFs Theme or any other thematic opportunities.
| View All Next | Launch |
Other Information on Investing in Clal Stock
To fully project Clal Biotechnology's future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of Clal Biotechnology at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include Clal Biotechnology's income statement, its balance sheet, and the statement of cash flows.